GLYCLOPYRAMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H14ClN3O3S
Molecular Weight	303.765
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCC2

InChI

InChIKey=HNSCCNJWTJUGNQ-UHFFFAOYSA-N

InChI=1S/C11H14ClN3O3S/c12-9-3-5-10(6-4-9)19(17,18)14-11(16)13-15-7-1-2-8-15/h3-6H,1-2,7-8H2,(H2,13,14,16)

HIDE SMILES / InChI

Description
Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/DEAMELIN_S_Tablets.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/14570054

Glyclopyramide (N-p-chlorobenzene sul-fonyl, N'-pyrrolidinourea) marketed under the tradename Deamelin-S is a sulfonylurea drug used in the treatment of diabetes mellitus. It has been marketed in Japan.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/DEAMELIN_S_Tablets.pdf	Primary		Approved 8583	DEAMELIN®·S Approved Use Unknown

C_max

Value	Dose	Analyte	Population
0.37 μg/L CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1600-0773.1998.tb01456.x	50 μg/kg single, oral dose: 50 μg/kg route of administration: Oral experiment type: SINGLE co-administered:	GLYCLOPYRAMIDE plasma	Homo sapiens population: HEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
0.76 μg/L CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	GLYCLOPYRAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.47 μg/L CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	8 μg/kg single, intramuscular dose: 8 μg/kg route of administration: Intramuscular experiment type: SINGLE co-administered:	GLYCLOPYRAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
276.3 μg × min/L CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1600-0773.1998.tb01456.x	5 μg/kg single, intravenous dose: 5 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GLYCLOPYRAMIDE plasma	Homo sapiens population: HEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
106.6 μg × min/L CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1600-0773.1998.tb01456.x	50 μg/kg single, oral dose: 50 μg/kg route of administration: Oral experiment type: SINGLE co-administered:	GLYCLOPYRAMIDE plasma	Homo sapiens population: HEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
8.64 μg × h/L CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	6 μg/kg single, intravenous dose: 6 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GLYCLOPYRAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.2 μg × h/L CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	GLYCLOPYRAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.2 μg × h/L CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	8 μg/kg single, intramuscular dose: 8 μg/kg route of administration: Intramuscular experiment type: SINGLE co-administered:	GLYCLOPYRAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
139 min CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1600-0773.1998.tb01456.x	5 μg/kg single, intravenous dose: 5 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		GLYCLOPYRAMIDE plasma	Homo sapiens population: HEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
0.83 h CLINICAL TRIAL https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	6 μg/kg single, intravenous dose: 6 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		GLYCLOPYRAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1500 mg 3 times / day multiple, oral Highest studied dose Dose: 1500 mg, 3 times / day Route: oral Route: multiple Dose: 1500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5811101/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/5811101/	Other AEs: Malaise... Other AEs: Malaise Sources: https://pubmed.ncbi.nlm.nih.gov/5811101/

AEs

AE	Significance	Dose	Population
Malaise		1500 mg 3 times / day multiple, oral Highest studied dose Dose: 1500 mg, 3 times / day Route: oral Route: multiple Dose: 1500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5811101/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/5811101/

PubMed

Title	Date	PubMed
[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].	2003	14570054

Patents

Sample Use Guides

In Vivo Use Guide

oral use is 125 to 250 mg daily, and as required, may be increased to determine a maintenance dose, with the upper limit of 500 mg daily

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

GLYCLOPYRAMIDE

Official Name

English

DEAMELIN-S

Preferred Name

English

glyclopyramide [INN]

Common Name

English

GLYCLOPYRAMIDE [JAN]

Common Name

English

1-((P-CHLOROPHENYL)SULFONYL)-3-(1-PYRROLIDINYL)UREA

Common Name

English

GLYCLOPYRAMIDE [MART.]

Common Name

English

Glyclopyramide [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C97936